Gene therapy-focused biotechs are realigning operations in response to financial and clinical challenges. Rocket Pharmaceuticals announced a 30% workforce reduction as part of efforts to reduce cash burn by 25%, focusing on cardiovascular gene therapies and de-prioritizing its Fanconi anemia program. Sarepta Therapeutics conducted layoffs following safety issues and shipping halts related to its Duchenne muscular dystrophy gene therapy Elevidys. Tessera also implemented job cuts amid fiscal constraints. These restructurings reflect the volatility and high stakes in advanced therapy development, with companies adjusting resources to sustain pipeline progression and market positioning.